Idorsia raises Sfr505m through share sale and CB to fund R&D

Idorsia, the Swiss biopharmaceutical company, has raised Sfr505m ($503.82m) to finance advanced clinical trials after a simultaneous share and convertible bond sale overnight in Zurich.

  • By Aidan Gregory
  • 11 Jul 2018

Credit Suisse and Goldman Sachs ran the books on both deals, which were launched after the market closed on Tuesday evening.

The Sfr305m share capital increase consisted of 11.9m shares, while the Sfr200m senior unsecured bonds are due in 2024 and had an initial coupon range of ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 219,258.01 824 8.16%
2 JPMorgan 208,215.92 896 7.75%
3 Bank of America Merrill Lynch 191,951.67 639 7.14%
4 Barclays 168,011.84 595 6.25%
5 HSBC 149,519.66 684 5.56%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 JPMorgan 29,830.94 52 6.95%
2 BNP Paribas 28,159.68 110 6.56%
3 UniCredit 22,060.45 102 5.14%
4 Credit Agricole CIB 22,050.13 103 5.13%
5 SG Corporate & Investment Banking 21,979.64 84 5.12%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Goldman Sachs 9,517.23 44 8.70%
2 JPMorgan 9,409.35 41 8.60%
3 Citi 7,643.16 42 6.99%
4 UBS 5,979.77 21 5.47%
5 Deutsche Bank 5,145.17 32 4.70%